We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
Vaccine 2009 November 6
Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000-2006, incorporating direct and indirect effects on incidence of invasive pneumococcal disease (IPD), hospitalized pneumonia and otitis media. Before accounting for indirect effects, PCV7 cost $201,000 per life-year saved. After incorporating indirect effects on IPD, cost per life-year saved was $10,400. The presence of modest additional indirect effects against hospitalized pneumonia and otitis media in children may have resulted in overall cost savings.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app